Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
OV

NASDAQ · OVID

Ovid Therapeutics Inc.

Healthcare · Biotechnology

$2.63

Down-$0.07 (-2.59%)

Updated Sep 11, 2026, 3:55 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
117.35M
P/E ratio
-0.06
Dividend yield
0.00%
52-week range
$1.12 – $3.11
Volume
1.4M
Avg. volume
2.89M

Price performance

OVID price history

1M range · 20 trading sessions · Daily adjusted prices

OVID closed at $2.63 after 20 trading sessions, down 6.07% for the selected period.

Last close
$2.63
Period change
-6.07%
Period low
$2.63
Period high
$2.93
Daily close
View OHLC price history
OVID OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$2.68$2.70$2.61$2.631.4M
Sep 9, 2026$2.74$2.781$2.685$2.701.26M
Sep 8, 2026$2.75$2.81$2.73$2.751.15M
Sep 4, 2026$2.74$2.825$2.71$2.801.07M
Sep 3, 2026$2.80$2.83$2.73$2.781.36M
Sep 2, 2026$2.78$2.87$2.68$2.711.56M
Sep 1, 2026$2.65$2.78$2.64$2.761.29M
Aug 31, 2026$2.78$2.805$2.65$2.671.39M
Aug 28, 2026$2.87$2.93$2.76$2.801.67M
Aug 27, 2026$2.85$2.95$2.83$2.931.72M
Aug 26, 2026$2.905$2.93$2.8449$2.881.14M
Aug 25, 2026$2.85$2.94$2.815$2.911.45M
Aug 24, 2026$2.79$2.86$2.67$2.821.23M
Aug 21, 2026$2.76$2.83$2.71$2.801.33M
Aug 20, 2026$2.88$2.93$2.72$2.741.15M
Aug 19, 2026$2.90$2.95$2.84$2.932.88M
Aug 18, 2026$2.87$2.905$2.795$2.841.94M
Aug 17, 2026$2.83$2.92$2.80$2.891.75M
Aug 14, 2026$2.80$2.87$2.745$2.831.24M
Aug 13, 2026$2.65$2.875$2.62$2.802.24M

Latest OVID news

The latest Smart Investors Daily articles mentioning OVID.

Stock researchCompany · Overview

OVID research

Overview

Company profile and research snapshot.

Company profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.50
Implied upside
—
Analysts
—
OVID recent ratings
DateFirmRatingTarget
Aug 3, 2026OppenheimerOutperform—
Apr 15, 2026WedbushOutperform—
Apr 9, 2026HC Wainwright & Co.Buy—
Mar 26, 2026BTIGBuy—
Mar 20, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Ovid Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ETH.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET Webcasts of the pre

Yahoo · Aug 13, 2026

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA newly-formed portfolio company with funds advised by Perceptive Advisors acquired global rights to soticlestat; Ovid secured equity in the company and the potential to receive regulatory and sales milestone payments and royalties upon successStrengthened executive leadership team with appointment of Kev

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By